Discussion
The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical trial testing MGX-001, the company’s experimental gene-editing therapy for hemophilia A. The Phase 1/2 trial, dubbed INTEGR8, aims to test the safety and tolerability of MGX-001 and identify optimal…